Society for Melanoma Research (SMR) 2016 Congress
November 6, 2016 to November 9, 2016
After signing in, to complete the evaluation and print your certificate please:
- Select Start in the Course Summary box to the right
- A confirmation page will then display, please select the Continue button
- You will then be directed to the evaluation, once complete please select the Submit button at the bottom
- You will then be asked how many credits you are claiming, complete all the fields, check the attestation box, and select Claim Credits
- A confirmation will display detailing the credits awarded.
- Please select the Next button to proceed to downloading your certificate.
After participating in this program, clinicians should be better able to:
- Discuss the latest research findings on melanoma causation, susceptibility, epidemiology, as well as the importance of prevention and early diagnosis
- Demonstrate an understanding of clinically important breakthroughs in melanoma genetics and genomics, including the emerging role of molecular testing on therapy decisions
- Describe the role of normal and mutated BRAF in intracellular signaling and explain the rationale for BRAF and MEK inhibition in the treatment of melanoma
- Assess the impact of new therapies on overall survival in metastatic melanoma
- Describe the process of T-cell activation and checkpoints to control T-cell activity
- Identify the 4 patterns of response to immunotherapy and apply new immune-related response criteria (irRC)
- Monitor for and promptly treat immune-related adverse events (IRAEs) in patients taking newer therapies for metastatic melanoma
- Evaluate ongoing investigations of treatments for metastatic melanoma, including optimizing patient selection for clinical trials.
Marriott Copley Place
- 20.00 AMA PRA Category 1 Credit(s)™
- 20.00 Attendance